Skip to content
CancerIndex

Publication

LAPTM4B promotes gefitinib resistance and tumor stemness in non-small cell lung cancer by stabilizing RPS3 through inhibiting its ubiquitination.

Yu Jiang, Wen-Jing Xie, Rong-Wei Chen, Chun-Li Huang, Wang-Qiu You, Hong Chen, Wei-Wei You, Wen-Xu Chen, Shaohan Xu, Jian-Ping Xu

Biochimica et biophysica acta. Molecular cell researchOct 1, 2026PMID 42612828doi:10.1016/j.bbamcr.2026.120212 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 11, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260911-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Gefitinib resistance remains a major obstacle to the effective treatment of non-small cell lung cancer (NSCLC), and the underlying molecular mechanisms have not yet been fully elucidated. Lysosomal-associated transmembrane protein 4B (LAPTM4B) has been shown to be involved in cancer progression,…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.